Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Fischer received his undergraduate degree from the University of Geneva and his medical degree from the Geneva Medical School, Switzerland.Myesha Lacy is Adverum’s vice president of investor relations and corporate communications and joined the Company in August 2019. Mr. Machado has 20 years of experience with biopharmaceutical companies leading finance, business development, and legal functions. Previously at Genentech, he led ophthalmology pipeline strategy and worked on Lucentis, leading several marketing teams and planning for wet age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) launches, as well as on the Port Delivery System. After serving in academia at the University of North Carolina School of Medicine, the UCLA Fielding School of Public Health, and the University of California at Berkeley, Dr. Carter began his pharmaceutical career at Pharmacia in 1993.
Ms. Patterson currently serves on the board of directors for Nkarta, Inc.Mark Lupher, Ph.D. joined Adverum’s board in May 2019. Image: Logo.jpg . in Business from Holy Names University.Aaron Osborne, MBBS is Adverum’s chief medical officer and joined the Company in April 2019. These are effective but typically require eye injections every 4-12 weeks in order to maintain vision. Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum has a substantial opportunity to meaningfully elevate the standard of care for patients at risk of losing their vision. “We look forward to presenting data from all four cohorts by the end of this year. Ms. Patterson is also a Certified Public Accountant (inactive status). Previously, he served as chairman and chief executive officer of Jennerex, Inc., until its acquisition by SillaJen Biotherapeutics, Inc. from Harvard Law School and a B.A. Get the latest news and updates from Stockhouse on social media“Tom’s breadth of lifecycle leadership, product marketing, and sales management expertise along with his 10 years of experience in the ophthalmology franchise at Genentech makes him an exceptional addition to our team,” said Leone Patterson, president of Adverum. Adverum Biotechnologies, Inc., 800 Saginaw Drive, Redwood City, CA 94063 Tel: 650-656-9323 Fax: 650.329.8151 General Inquiry: info@adverum.com Inquiry Type* * Please Select General Inquiry Careers Business Development "We are delighted to welcome an experienced industry leader of Laurent's caliber to our team at Adverum," said Patrick Machado, J.D., Board Chair of Adverum. Dr. Fischer currently serves as chairman of the board of CTI Biopharma, as director at Mirum Pharmaceuticals, Inc. and Lycia Therapeutics, and as senior advisor on the Life Sciences Team at Frazier Healthcare Partners.